The Experts below are selected from a list of 8157 Experts worldwide ranked by ideXlab platform

Avi Livneh - One of the best experts on this subject based on the ideXlab platform.

  • Colchicine nonresponsiveness in familial mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization
    Seminars in Arthritis and Rheumatism, 2004
    Co-Authors: Merav Lidar, Elisabeth Niel, Ruth Gershoni-baruch, Yael Shinar, Jean Michel Scherrmann, Angela Chetrit, Pnina Langevitz, Avi Livneh
    Abstract:

    Abstract Objectives To identify the ethnic, clinical, genetic, and pharmacokinetic correlates of Colchicine Treatment failure in patients with familial Mediterranean fever (FMF). Methods Fifty-nine FMF patients, unresponsive to a daily dose of ≥2 mg Colchicine, were compared with 51 Colchicine-responsive patients by clinical, demographic, and socioeconomic assessment, FMF gene (MEditerranean FeVer [ MEFV ]) mutation and serum amyloid A1 ( SAA1 ) gene polymorphism analysis, and plasma and white blood cell Colchicine level determination. Results Colchicine responders and nonresponders were comparable with respect to gender, age, duration and onset of the disease, and various demographic parameters. The 2 cohorts were found to carry mainly the M694V MEFV mutation and had a similar number of homozygotes or compound heterozygotes. Predominance of the α/β alleles of SAA1 and comparable plasma and polymorphonuclear Colchicine concentrations characterized both groups. Nonresponders were from lower socioeconomic backgrounds, had less education, and a more severe form of disease. A statistically significant 2-fold elevation of Colchicine concentration in the mononuclear cells (MNC) of responders was found. Conclusions Colchicine Treatment failure in FMF is associated with inadequate Colchicine MNC concentration, probably resulting from a genetic defect unrelated to the underlying FMF.

  • Colchicine Treatment of aa amyloidosis of familial mediterranean fever
    Arthritis & Rheumatism, 1994
    Co-Authors: Avi Livneh, Pnina Langevitz, Deborah Zemer, Ezra Sohar, Arie Laor, Mordechai Pras
    Abstract:

    OBJECTIVE To elucidate factors possibly influencing the outcome of Colchicine therapy in patients with amyloidosis of familial Mediterranean fever (FMF). METHODS Retrospective analysis of data abstracted from the charts of all 68 FMF patients with amyloidosis who presented during the study period (1974-1992) with proteinuria (> or = 0.5 gm/24 hours) and creatinine values or = 5 years. RESULTS At the end of the study period, kidney disease had worsened in 31 patients and remained stable in 22. Proteinuria had regressed in 15 patients. Deterioration was related to initial serum creatinine values > or = 1.5 mg/dl (P 1.5 mg/day. This dosage is effective only in patients with initial serum creatinine levels < 1.5 mg/dl.

  • Colchicine Treatment of aa amyloidosis of familial mediterranean fever an analysis of factors affecting outcome
    Arthritis & Rheumatism, 1994
    Co-Authors: Avi Livneh, Pnina Langevitz, Deborah Zemer, Ezra Sohar, Arie Laor, Mordechai Pras
    Abstract:

    OBJECTIVE To elucidate factors possibly influencing the outcome of Colchicine therapy in patients with amyloidosis of familial Mediterranean fever (FMF). METHODS Retrospective analysis of data abstracted from the charts of all 68 FMF patients with amyloidosis who presented during the study period (1974-1992) with proteinuria (> or = 0.5 gm/24 hours) and creatinine values or = 5 years. RESULTS At the end of the study period, kidney disease had worsened in 31 patients and remained stable in 22. Proteinuria had regressed in 15 patients. Deterioration was related to initial serum creatinine values > or = 1.5 mg/dl (P 1.5 mg/day. This dosage is effective only in patients with initial serum creatinine levels < 1.5 mg/dl.

  • long term Colchicine Treatment in children with familial mediterranean fever
    Arthritis & Rheumatism, 1991
    Co-Authors: Deborah Zemer, Avi Livneh, Y L Danon, Mordechai Pras, Ezra Sohar
    Abstract:

    Three hundred fifty children (younger than age 16) who had familial Mediterranean fever (FMF) were given continuous prophylactic Treatment with Colchicine (1-2 mg/day) for 6-13 years. Complete remission of febrile attacks was achieved in 64% of the patients, and partial remission in 31%. Protracted attacks of arthritis virtually disappeared. None of the children developed amyloidosis while on the Colchicine regimen. Side effects of Colchicine were insignificant, and did not prompt permanent discontinuation of Treatment in any of the children. Their growth, development, and subsequent fertility were normal. The efficacy of long-term Colchicine Treatment of children with FMF makes early diagnosis life saving.

Ezra Sohar - One of the best experts on this subject based on the ideXlab platform.

  • Colchicine Treatment of aa amyloidosis of familial mediterranean fever an analysis of factors affecting outcome
    Arthritis & Rheumatism, 1994
    Co-Authors: Avi Livneh, Pnina Langevitz, Deborah Zemer, Ezra Sohar, Arie Laor, Mordechai Pras
    Abstract:

    OBJECTIVE To elucidate factors possibly influencing the outcome of Colchicine therapy in patients with amyloidosis of familial Mediterranean fever (FMF). METHODS Retrospective analysis of data abstracted from the charts of all 68 FMF patients with amyloidosis who presented during the study period (1974-1992) with proteinuria (> or = 0.5 gm/24 hours) and creatinine values or = 5 years. RESULTS At the end of the study period, kidney disease had worsened in 31 patients and remained stable in 22. Proteinuria had regressed in 15 patients. Deterioration was related to initial serum creatinine values > or = 1.5 mg/dl (P 1.5 mg/day. This dosage is effective only in patients with initial serum creatinine levels < 1.5 mg/dl.

  • Colchicine Treatment of aa amyloidosis of familial mediterranean fever
    Arthritis & Rheumatism, 1994
    Co-Authors: Avi Livneh, Pnina Langevitz, Deborah Zemer, Ezra Sohar, Arie Laor, Mordechai Pras
    Abstract:

    OBJECTIVE To elucidate factors possibly influencing the outcome of Colchicine therapy in patients with amyloidosis of familial Mediterranean fever (FMF). METHODS Retrospective analysis of data abstracted from the charts of all 68 FMF patients with amyloidosis who presented during the study period (1974-1992) with proteinuria (> or = 0.5 gm/24 hours) and creatinine values or = 5 years. RESULTS At the end of the study period, kidney disease had worsened in 31 patients and remained stable in 22. Proteinuria had regressed in 15 patients. Deterioration was related to initial serum creatinine values > or = 1.5 mg/dl (P 1.5 mg/day. This dosage is effective only in patients with initial serum creatinine levels < 1.5 mg/dl.

  • long term Colchicine Treatment in children with familial mediterranean fever
    Arthritis & Rheumatism, 1991
    Co-Authors: Deborah Zemer, Avi Livneh, Y L Danon, Mordechai Pras, Ezra Sohar
    Abstract:

    Three hundred fifty children (younger than age 16) who had familial Mediterranean fever (FMF) were given continuous prophylactic Treatment with Colchicine (1-2 mg/day) for 6-13 years. Complete remission of febrile attacks was achieved in 64% of the patients, and partial remission in 31%. Protracted attacks of arthritis virtually disappeared. None of the children developed amyloidosis while on the Colchicine regimen. Side effects of Colchicine were insignificant, and did not prompt permanent discontinuation of Treatment in any of the children. Their growth, development, and subsequent fertility were normal. The efficacy of long-term Colchicine Treatment of children with FMF makes early diagnosis life saving.

Mordechai Pras - One of the best experts on this subject based on the ideXlab platform.

  • Colchicine Treatment of aa amyloidosis of familial mediterranean fever an analysis of factors affecting outcome
    Arthritis & Rheumatism, 1994
    Co-Authors: Avi Livneh, Pnina Langevitz, Deborah Zemer, Ezra Sohar, Arie Laor, Mordechai Pras
    Abstract:

    OBJECTIVE To elucidate factors possibly influencing the outcome of Colchicine therapy in patients with amyloidosis of familial Mediterranean fever (FMF). METHODS Retrospective analysis of data abstracted from the charts of all 68 FMF patients with amyloidosis who presented during the study period (1974-1992) with proteinuria (> or = 0.5 gm/24 hours) and creatinine values or = 5 years. RESULTS At the end of the study period, kidney disease had worsened in 31 patients and remained stable in 22. Proteinuria had regressed in 15 patients. Deterioration was related to initial serum creatinine values > or = 1.5 mg/dl (P 1.5 mg/day. This dosage is effective only in patients with initial serum creatinine levels < 1.5 mg/dl.

  • Colchicine Treatment of aa amyloidosis of familial mediterranean fever
    Arthritis & Rheumatism, 1994
    Co-Authors: Avi Livneh, Pnina Langevitz, Deborah Zemer, Ezra Sohar, Arie Laor, Mordechai Pras
    Abstract:

    OBJECTIVE To elucidate factors possibly influencing the outcome of Colchicine therapy in patients with amyloidosis of familial Mediterranean fever (FMF). METHODS Retrospective analysis of data abstracted from the charts of all 68 FMF patients with amyloidosis who presented during the study period (1974-1992) with proteinuria (> or = 0.5 gm/24 hours) and creatinine values or = 5 years. RESULTS At the end of the study period, kidney disease had worsened in 31 patients and remained stable in 22. Proteinuria had regressed in 15 patients. Deterioration was related to initial serum creatinine values > or = 1.5 mg/dl (P 1.5 mg/day. This dosage is effective only in patients with initial serum creatinine levels < 1.5 mg/dl.

  • long term Colchicine Treatment in children with familial mediterranean fever
    Arthritis & Rheumatism, 1991
    Co-Authors: Deborah Zemer, Avi Livneh, Y L Danon, Mordechai Pras, Ezra Sohar
    Abstract:

    Three hundred fifty children (younger than age 16) who had familial Mediterranean fever (FMF) were given continuous prophylactic Treatment with Colchicine (1-2 mg/day) for 6-13 years. Complete remission of febrile attacks was achieved in 64% of the patients, and partial remission in 31%. Protracted attacks of arthritis virtually disappeared. None of the children developed amyloidosis while on the Colchicine regimen. Side effects of Colchicine were insignificant, and did not prompt permanent discontinuation of Treatment in any of the children. Their growth, development, and subsequent fertility were normal. The efficacy of long-term Colchicine Treatment of children with FMF makes early diagnosis life saving.

Deborah Zemer - One of the best experts on this subject based on the ideXlab platform.

  • Colchicine Treatment of aa amyloidosis of familial mediterranean fever an analysis of factors affecting outcome
    Arthritis & Rheumatism, 1994
    Co-Authors: Avi Livneh, Pnina Langevitz, Deborah Zemer, Ezra Sohar, Arie Laor, Mordechai Pras
    Abstract:

    OBJECTIVE To elucidate factors possibly influencing the outcome of Colchicine therapy in patients with amyloidosis of familial Mediterranean fever (FMF). METHODS Retrospective analysis of data abstracted from the charts of all 68 FMF patients with amyloidosis who presented during the study period (1974-1992) with proteinuria (> or = 0.5 gm/24 hours) and creatinine values or = 5 years. RESULTS At the end of the study period, kidney disease had worsened in 31 patients and remained stable in 22. Proteinuria had regressed in 15 patients. Deterioration was related to initial serum creatinine values > or = 1.5 mg/dl (P 1.5 mg/day. This dosage is effective only in patients with initial serum creatinine levels < 1.5 mg/dl.

  • Colchicine Treatment of aa amyloidosis of familial mediterranean fever
    Arthritis & Rheumatism, 1994
    Co-Authors: Avi Livneh, Pnina Langevitz, Deborah Zemer, Ezra Sohar, Arie Laor, Mordechai Pras
    Abstract:

    OBJECTIVE To elucidate factors possibly influencing the outcome of Colchicine therapy in patients with amyloidosis of familial Mediterranean fever (FMF). METHODS Retrospective analysis of data abstracted from the charts of all 68 FMF patients with amyloidosis who presented during the study period (1974-1992) with proteinuria (> or = 0.5 gm/24 hours) and creatinine values or = 5 years. RESULTS At the end of the study period, kidney disease had worsened in 31 patients and remained stable in 22. Proteinuria had regressed in 15 patients. Deterioration was related to initial serum creatinine values > or = 1.5 mg/dl (P 1.5 mg/day. This dosage is effective only in patients with initial serum creatinine levels < 1.5 mg/dl.

  • long term Colchicine Treatment in children with familial mediterranean fever
    Arthritis & Rheumatism, 1991
    Co-Authors: Deborah Zemer, Avi Livneh, Y L Danon, Mordechai Pras, Ezra Sohar
    Abstract:

    Three hundred fifty children (younger than age 16) who had familial Mediterranean fever (FMF) were given continuous prophylactic Treatment with Colchicine (1-2 mg/day) for 6-13 years. Complete remission of febrile attacks was achieved in 64% of the patients, and partial remission in 31%. Protracted attacks of arthritis virtually disappeared. None of the children developed amyloidosis while on the Colchicine regimen. Side effects of Colchicine were insignificant, and did not prompt permanent discontinuation of Treatment in any of the children. Their growth, development, and subsequent fertility were normal. The efficacy of long-term Colchicine Treatment of children with FMF makes early diagnosis life saving.

Margaret W Mwathi - One of the best experts on this subject based on the ideXlab platform.

  • fertile allohexaploid brassica hybrids obtained from crosses between b oleracea and b juncea via ovule rescue and Colchicine Treatment of cuttings
    Plant Cell Tissue and Organ Culture, 2020
    Co-Authors: Margaret W Mwathi, Mehak Gupta, Daniela Quezadamartinez, Aneeta Pradhan, J R Batley, Annaliese S Mason
    Abstract:

    An allohexaploid Brassica crop (2n = AABBCC) does not exist naturally, but is of interest for its potential to combine useful traits found in the six cultivated Brassica species which share combinations of the A, B and C genomes with additional allelic heterosis. In this study, we aimed to produce 2n = AABBCC hybrids by crosses between B. juncea and a number of Brassica C genome species. We used ovule rescue to overcome hybridization barriers and different Colchicine Treatment methods to induce chromosome doubling of ABC hybrids to AABBCC allohexaploids, thus restoring fertility. Only the cross B. oleracea × B. juncea was successful, with six triploid hybrids produced from one genotype combination. Colchicine-containing regeneration media was unsuccessful in doubling chromosome number in these hybrids, but Treatment of cuttings with 0.05 to 0.25% Colchicine successfully produced ~ 200 S1 allohexaploid seeds. The S1 plants produced 7–84% viable pollen and set 0–390 seeds per plant, with 23–27 bivalents and 0–3 univalents during metaphase I of meiosis. Our results highlight the difficulties in working with the wild C genome species, but showed that our methods have utility for producing euploid, chromosome-doubled progeny in this cross combination. Further, Brassica oleracea × B. juncea allohexaploid hybrids may contain useful genetic factors for improved meiotic stability and fertility in allohexaploid germplasm pools. Ovule rescue followed by 0.05–0.25% Colchicine Treatment of cuttings successfully produces fertile, partially stable allohexaploid Brassica from the cross B. juncea × B. oleracea.